Androgen receptor levels are upregulated by Akt in prostate cancer

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 245-255

  Ha, Susan ^a   Ruoff, Rachel ^a   Kahoud, Nicole ^a,b   Franke, Thomas F ^a   Logan, Susan K ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHECKPOINT KINASE 2; HISTONE H2AX; MESSENGER RNA; PROTEIN GAMMA H2AX; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; REGULATORY MECHANISM; TRANSGENIC ORGANISM; UPREGULATION;

ANDROGENS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; HISTONES; HUMANS; MALE; METRIBOLONE; MICE; MICE, TRANSGENIC; MORPHOLINES; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79953179324     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0204     Document Type: Article

References (36)

1. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC et al. 2006 Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 633-637. (doi:10.1038/nature05268)
2. Bookout AL & Mangelsdorf DJ 2003 Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nuclear Receptor Signaling 1 e012. (doi:10.1621/nrs.01012)
3. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR et al. 2007 The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clinical Genitourinary Cancer 5 433-437. (doi:10.3816/CGC. 2007.n.031)
4. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H & Qiu Y 2001 Regulation of Akt/PKB activation by tyrosine phosphorylation. Journal of Biological Chemistry 276 31858-31862. (doi:10.1074/jbc.C100271200)
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
6. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W et al. 2005 Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 725-730. (doi:10.1038/nature03918)
7. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M et al. 2005 Tumour biology: senescence in premalignant tumours. Nature 436 642. (doi:10.1038/436642a)
8. Conus NM, Hannan KM, Cristiano BE, Hemmings BA & Pearson RB 2002 Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. Journal of Biological Chemistry 277 38021-38028. (doi:10.1074/jbc.M203387200)
9. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K et al. 1999 Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 242-251. (doi:10.1038/sj.bjc.6690684)
10. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP & Baldwin AS 2008 Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes and Development 22 1490-1500. (doi:10.1101/gad. 1662308)
11. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW et al. 2005 Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Molecular Cancer Therapeutics 4 271-279. (Pubitemid 40340206)
12. Di Cristofano A, Pesce B, Cordon-Cardo C & Pandolfi PP 1998 Pten is essential for embryonic development and tumour suppression. Nature Genetics 19 348-355. (doi:10.1038/1235)
13. Gao M, Ossowski L & Ferrari AC 1999 Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. Journal of Cellular Physiology 179 336-346. (doi:10.1002/(SICI)1097-4652(199906) 179:3〈336::AID-JCP11〉3.0.CO;2-Q)
14. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B et al. 2005 Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 907-913. (doi:10.1038/nature03485)
15. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS & Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 4315-4319. (Pubitemid 32685750)
16. Ko S, Shi L, Kim S, Song CS & Chatterjee B 2008 Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Molecular Endocrinology 22 273-286. (doi:10.1210/me.2007-0332)
17. Koseoglu S, Lu Z, Kumar C, Kirschmeier P & Zou J 2007 AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biology & Therapy 6 755-762. (doi:10.4161/cbt.6.5.3995)
18. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM & Saad F 2006 Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. British Journal of Cancer 94 1906-1912. (doi:10.1038/sj.bjc.6603184)
19. Li X, Lu Y, Jin W, Liang K, Mills GB & Fan Z 2006 Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. Journal of Biological Chemistry 281 13837-13843. (doi:10.1074/jbc.M602060200)
20. Liang J & Slingerland JM 2003 Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 339-345. (doi:10.4161/cc.2.4. 433)
21. Lin HK, Wang L, Hu YC, Altuwaijri S & Chang C 2002 Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO Journal 21 4037-4048. (doi:10.1093/emboj/ cdf406)
22. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY & Chang C 2003 Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. Journal of Biological Chemistry 278 50902-50907. (doi:10.1074/jbc.M300676200)
23. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE et al. 2005 Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorganic and Medicinal Chemistry Letters 15 761-764. (doi:10.1016/j.bmcl.2004.11.011)
24. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR et al. 2003 Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. PNAS 100 7841-7846. (doi:10.1073/pnas.1232229100)
25. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R et al. 2008 A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14 146-155. (doi:10.1016/j.ccr.2008.06.002)
26. Manning BD & Cantley LC 2007 AKT/PKB signaling: navigating downstream. Cell 129 1261-1274. (doi:10.1016/j.cell.2007.06.009)
27. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ & Peeper DS 2005 BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 720-724. (doi:10.1038/nature03890)
28. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A et al. 2005 A phase II study of perifosine in androgen independent prostate cancer. Cancer Biology & Therapy 4 1133-1137. (doi:10.4161/cbt.4.10.2064)
29. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J, Shapiro E, Garabedian MJ &Logan SK 2005 Cell-specific regulation of androgen receptor phosphorylation in vivo. Journal of Biological Chemistry 280 40916-40924. (doi:10.1074/jbc.M508442200)
30. WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Research 61 7544-7551.
31. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 209-221. (doi:10.1016/S1535-6108(03)00215-0)
32. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
33. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK & Witte ON 2006 Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. PNAS 103 7789-7794. (doi:10.1073/pnas.0602567103)
34. Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M & Sellers WR 2007 Identification of prostate cancer modifier pathways using parental strain expression mapping. PNAS 104 17771-17776. (doi:10.1073/pnas.0708476104)
35. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH et al. 2005 Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. Journal of Biological Chemistry 280 33558-33565. (doi:10.1074/jbc.M504461200)
36. Zhang J, Thomas TZ, Kasper S & Matusik RJ 2000 A small composite probasin promoter confers high levels of prostate- specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141 4698-4710. (doi:10.1210/en.141.12.4698)